RARITAN, N.J.--(BUSINESS WIRE)--Jeff Capello, Chief Financial Officer of Ortho Clinical Diagnostics (OCD) has decided to leave OCD for personal reasons.
Jeff has been part of the new OCD executive leadership team that was formed on June 30, 2014 when the sale of OCD to Carlyle was officially completed. Under Jeff’s leadership the new OCD stand-alone finance functions have been built and a number of our financial processes have been greatly strengthened. In his tenure at OCD, Jeff has made important contributions in the early phase of our transformation and leaves the finance organization substantially improved with great leaders in place.
We wish Jeff the best as he pursues the next stage of his career. Jeff’s last day at OCD will be June 12, 2015 and he has agreed to support the new CFO during the transition.
I am also pleased to announce that Charles F. Wagner, Jr. will become Chief Financial Officer of OCD, effective June 24, 2015.
Charlie is currently Executive Vice President and Chief Financial Officer at Bruker Corporation (NASDAQ: BRKR), a publicly-traded life sciences company. I have known Charlie since 2004 and worked closely with him at Millipore Corporation where he was CFO until its successful sale to Merck in 2010. I am extremely pleased to have hired such a qualified and talented finance professional to take the reins as CFO. Charlie has a strong track record of creating positive change, possesses excellent leadership and communication skills and has a demonstrated ability of delivering outstanding performance in global manufacturing companies.
For further questions please contact John Sanders, Treasurer, at 908-655-2466 (email@example.com).
Chairman and CEO
Ortho Clinical Diagnostics